Neuropharmacology and Aging
- 1 January 1978
- book chapter
- Published by Springer Nature
- Vol. 97, 171-185
- https://doi.org/10.1007/978-1-4684-7793-1_10
Abstract
It is difficult to discuss the subject of the neuropharmacology of aging when it is well known that we presently have very few agents which can be classified as such. Many psychotropic drugs are used in the elderly, either to treat specific neuropsychiatric disorders, or in an attempt to treat the signs and symptoms associated with the “organic brain syndromes.” In the former cases the therapeutic approach is straightforward provided appropriate precautions and hazards specific to the elderly be recognized (1–3). It is in the latter cases, the “organic brain syndromes,” where pharmacological intervention has met essentially without success, and where the greatest need exists for the development of newer therapeutic agents.Keywords
This publication has 20 references indexed in Scilit:
- Norepinephrine-Dopamine Interactions and BehaviorScience, 1977
- Experimental pathology and pharmacology in brain research and agingLife Sciences, 1975
- POTENTIATION OF LEVODOPA EFFECT BY INTRAVENOUS L-PROLYL-L-LEUCYL-GLYCINE AMIDE IN MANThe Lancet, 1975
- Dopamine and the pharmacology of schizophrenia: The state of the evidenceJournal of Psychiatric Research, 1974
- Antipsychotic drugs and catecholamine synapsesJournal of Psychiatric Research, 1974
- Drugs, Neurotransmitters, and SchizophreniaScience, 1974
- Possible Etiology of Schizophrenia: Progressive Damage to the Noradrenergic Reward System by 6-HydroxydopamineScience, 1971
- THE CYTOCHEMISTRY AND ULTRASTRUCTURE OF POLYPEPTIDE HORMONE-PRODUCING CELLS OF THE APUD SERIES AND THE EMBRYOLOGIC, PHYSIOLOGIC AND PATHOLOGIC IMPLICATIONS OF THE CONCEPTJournal of Histochemistry & Cytochemistry, 1969
- Cardiac Monoamine Oxidase in RatNature, 1967
- Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine1Journal of the American Chemical Society, 1959